20-206 - Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
Status: openACNS1422-A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Treatment for Pediatric Oncology - Medulloblastoma
Contact Us
If you have questions about this trial or are interested in participating, please contact this Clinical Trial’s Coordinator by email at clinical.trials@health.southalabama.edu.
Description
To estimate the progression-free survival (PFS) of children ≥ 3 years of age with WNT-driven average-risk medulloblastoma using reduced craniospinal radiotherapy (CSI) (18 Gy) with a limited target volume boost to the tumor bed of 36 Gy for a total of 54 Gy and reduced chemotherapy approach (no vincristine during radiotherapy and reduced-dose maintenance chemotherapy) and to monitor the PFS for early evidence that the outcome is unacceptable.
